ISSUER ANNOUNCEMENT · EIN PRESSWIRE
Jocasta Neuroscience & Diamond Therapeutics to Research Novel Compounds for Cognitive Impairment, Neurodegeneration
Supplied by the issuer through EIN Presswire. This announcement is separate from Factavelle’s reporting; its claims have not been independently verified. Feed wording is preserved, with formatting adapted for readability.
Joint research program will evaluate three non-hallucinogenic psychedelic-inspired compounds designed to replicate psilocybin's therapeutic effects
TORONTO, ON, CANADA, October 13, 2026 /EINPresswire.com/ -- Jocasta Neuroscience, Inc. (“ …